Ruiqi Zhang

Lika, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Antiviral activities of multiple antivirals against highly pathogenic avian influenza A H5N1 in vitro and in mice.

Antiviral activities of multiple antivirals against highly pathogenic avian influenza A H5N1 in vitro and in mice.

Journal: Emerging microbes & infections

Published: March 31, 2026

Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies.

Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies.

Journal: Influenza and other respiratory viruses

Published: June 05, 2025

Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.

Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.

Journal: Journal of medical virology

Published: June 17, 2024

Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.

Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.

Journal: The Lancet. Infectious diseases

Published: February 27, 2024

Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.

Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.

Journal: Virus research

Published: February 02, 2024

CS-2034 mRNA vaccine: a new option for COVID-19 infection?

CS-2034 mRNA vaccine: a new option for COVID-19 infection?

Journal: The Lancet. Infectious diseases

Published: April 10, 2023

The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What.

The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What.

Journal: Vaccines

Published: October 08, 2022

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.

Journal: mSphere

Published: March 14, 2022

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.

Journal: Vaccines

Published: December 31, 2021

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 12, 2021

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.

Journal: Vaccines

Published: November 23, 2021

Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.

Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.

Journal: Vaccines

Published: November 05, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026